Cumberland takes $100M cash deal, keeps three Phase II programs
Shareholders must approve the Apotex transaction. Cumberland keeps majority ownership in CET, with top-line systemic sclerosis data next.
Shareholders must approve the Apotex transaction. Cumberland keeps majority ownership in CET, with top-line systemic sclerosis data next.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
